Acetaminophen side effects: what 444,741 FDA adverse event reports show
Drug class
Not stated in label
Who reports
444,741 reports · 72% serious · 62,469 with death outcome · 65% female
Used for
Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.
What it is
Paracetamol is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Boxed warning
RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Blood pressure diastolic abnormal | 1,876 | 129.1 118.2–141.1ROR 129.7 · calibrated p 2e-8 ✓ | 34.4 EB05 33.1 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious n=1,781 · 90% clinician | no trial arm names this drug |
| Blood pressure systolic abnormal | 1,720 | 106.0 97.3–115.6ROR 106.4 · calibrated p 7e-8 ✓ | 32.5 EB05 31.3 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=1,635 · 90% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 454 | 100.8 85.4–118.8ROR 100.9 · calibrated p 1e-7 ✓ | 32.0 EB05 29.6 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=454 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Lupus vulgaris | 792 | 94.1 83.3–106.3ROR 94.2 · calibrated p 2e-7 ✓ | 31.3 EB05 29.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=792 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 4,606 | 87.0 82.8–91.4ROR 87.9 · calibrated p 3e-7 ✓ | 30.5 EB05 29.8 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious PRR 24.4 · ♀ 100% (drug 65%) · 94% clinician | no trial arm names this drug |
| Rheumatic fever | 2,807 | 84.8 79.7–90.3ROR 85.4 · calibrated p 4e-7 ✓ | 30.3 EB05 29.3 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=2,806 · ♀ 100% (drug 65%) · 94% clinician | no trial arm names this drug |
| Swollen joint count increased | 1,976 | 81.5 75.7–87.7ROR 81.9 · calibrated p 5e-7 ✓ | 29.8 EB05 28.7 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=1,973 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 1,242 | 81.4 74.2–89.3ROR 81.6 · calibrated p 5e-7 ✓ | 29.8 EB05 28.4 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=1,242 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| C-reactive protein | 568 | 78.8 68.8–90.2ROR 78.9 · calibrated p 7e-7 ✓ | 29.4 EB05 27.5 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=568 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 4,564 | 77.4 73.8–81.2ROR 78.2 · calibrated p 7e-7 ✓ | 29.3 EB05 28.6 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 23.3 · ♀ 100% (drug 65%) · 94% clinician | no trial arm names this drug |
| Facet joint syndrome | 1,725 | 56.6 52.7–60.7ROR 56.8 · calibrated p 6e-6 ✓ | 25.8 EB05 24.8 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=1,721 · ♀ 100% (drug 65%) · 94% clinician | no trial arm names this drug |
| Exposure to toxic agent | 1,706 | 52.7 49.1–56.5ROR 52.9 · calibrated p 1e-5 ✓ | 24.9 EB05 24.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=1,697 · 100% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 2,920 | 47.9 45.5–50.4ROR 48.2 · calibrated p 2e-5 ✓ | 23.8 EB05 23.1 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=2,919 · ♀ 100% (drug 65%) · 95% clinician | no trial arm names this drug |
| Muscle injury | 3,986 | 44.1 42.2–46.0ROR 44.5 · calibrated p 3e-5 ✓ | 22.9 EB05 22.3 · IC025 +4.5 3/3 methods agree | Labeled (related wording) related wording | serious PRR 19.7 · ♀ 100% (drug 65%) · 92% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 978 | 44.0 40.3–48.0ROR 44.1 · calibrated p 3e-5 ✓ | 22.8 EB05 21.7 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=973 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 2,974 | 40.0 38.1–42.0ROR 40.3 · calibrated p 5e-5 ✓ | 21.8 EB05 21.1 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=2,956 · ♀ 100% (drug 65%) · 93% clinician | no trial arm names this drug |
| Helicobacter infection | 4,707 | 40.0 38.5–41.6ROR 40.4 · calibrated p 5e-5 ✓ | 21.7 EB05 21.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 18.2 · ♀ 100% (drug 65%) · 93% clinician | no trial arm names this drug |
| X-ray abnormal | 801 | 37.9 34.5–41.6ROR 38.0 · calibrated p 7e-5 ✓ | 21.1 EB05 19.9 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=801 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Folliculitis | 4,524 | 36.3 34.9–37.7ROR 36.7 · calibrated p 9e-5 ✓ | 20.6 EB05 20.1 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 19.2 · ♀ 100% (drug 65%) · 93% clinician | no trial arm names this drug |
| Dislocation of vertebra | 973 | 36.2 33.3–39.4ROR 36.3 · calibrated p 9e-5 ✓ | 20.6 EB05 19.5 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=973 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Pemphigus | 5,229 | 33.8 32.6–35.0ROR 34.2 · calibrated p 1e-4 ✓ | 19.8 EB05 19.4 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 15.8 · ♀ 100% (drug 65%) · 93% clinician | no trial arm names this drug |
| Hand deformity | 5,417 | 32.9 31.8–34.0ROR 33.3 · calibrated p 1e-4 ✓ | 19.5 EB05 19.1 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 16.8 · ♀ 100% (drug 65%) · 91% clinician | no trial arm names this drug |
| Analgesic drug level increased | 604 | 27.7 25.0–30.6ROR 27.7 · calibrated p 4e-4 ✓ | 17.6 EB05 16.4 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=603 · 100% clinician | no trial arm names this drug |
| Autism spectrum disorder | 2,018 | 27.2 25.7–28.7ROR 27.3 · calibrated p 4e-4 ✓ | 17.4 EB05 16.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=2,017 · ♀ 31% (drug 65%) · 100% consumer | no trial arm names this drug |
| Retinitis | 605 | 26.4 23.9–29.2ROR 26.4 · calibrated p 5e-4 ✓ | 17.1 EB05 15.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=605 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Peripheral venous disease | 1,405 | 25.2 23.6–26.9ROR 25.3 · calibrated p 6e-4 ✓ | 16.6 EB05 15.9 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=1,395 · ♀ 100% (drug 65%) · 90% clinician | no trial arm names this drug |
| Synovitis | 6,150 | 24.0 23.3–24.7ROR 24.3 · calibrated p 8e-4 ✓ | 16.1 EB05 15.7 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious PRR 13.4 · ♀ 97% (drug 65%) · 90% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 2,113 | 22.8 21.7–24.1ROR 22.9 · calibrated p 0.001 ✓ | 15.5 EB05 15.0 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=2,108 · ♀ 100% (drug 65%) · 92% clinician | no trial arm names this drug |
| Pericarditis | 5,346 | 21.9 21.2–22.6ROR 22.2 · calibrated p 0.001 ✓ | 15.1 EB05 14.8 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious PRR 12.1 · ♀ 98% (drug 65%) · 92% clinician | no trial arm names this drug |
| Infusion site discharge | 465 | 17.3 15.5–19.2ROR 17.3 · calibrated p 0.004 ✓ | 12.8 EB05 11.8 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious n=351 · ♀ 100% (drug 65%) · 100% consumer | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 5,431 | 14.9 14.4–15.3ROR 15.0 · calibrated p 0.007 ✓ | 11.4 EB05 11.2 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious PRR 12.8 · ♀ 98% (drug 65%) | no trial arm names this drug |
| Sedation complication | 593 | 14.4 13.1–15.8ROR 14.4 · calibrated p 0.008 ✓ | 11.1 EB05 10.4 · IC025 +3.3 3/3 methods agree | Reporting / coding artifact | serious n=588 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Acute hepatic failure | 3,176 | 14.1 13.6–14.7ROR 14.2 · calibrated p 0.009 ✓ | 11.0 EB05 10.7 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 10.9 · serious PRR 8.8 · 92% clinician | no trial arm names this drug |
| Bursitis | 2,775 | 13.8 13.2–14.4ROR 13.9 · calibrated p 0.009 ✓ | 10.8 EB05 10.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 10.0 · ♀ 96% (drug 65%) | no trial arm names this drug |
| Blood pressure diastolic decreased | 1,704 | 13.8 13.1–14.6ROR 13.9 · calibrated p 0.010 ✓ | 10.8 EB05 10.4 · IC025 +3.4 3/3 methods agree | Lab value / disease marker | serious PRR 8.8 | no trial arm names this drug |
| Irritable bowel syndrome | 4,860 | 13.6 13.2–14.1ROR 13.8 · calibrated p 0.010 ✓ | 10.7 EB05 10.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 10.6 · ♀ 97% (drug 65%) | no trial arm names this drug |
| Temperature regulation disorder | 486 | 13.2 12.0–14.6ROR 13.2 · calibrated p 0.012 ✓ | 10.4 EB05 9.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=478 · ♀ 100% (drug 65%) | no trial arm names this drug |
| Bone erosion | 787 | 13.2 12.2–14.3ROR 13.2 · calibrated p 0.012 ✓ | 10.4 EB05 9.8 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=786 · ♀ 100% (drug 65%) · 100% clinician | no trial arm names this drug |
| Infusion site pruritus | 670 | 12.7 11.6–13.8ROR 12.7 · calibrated p 0.014 ✓ | 10.1 EB05 9.5 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=388 | no trial arm names this drug |
| Hyperparathyroidism secondary | 543 | 12.6 11.5–13.9ROR 12.6 · calibrated p 0.014 ✓ | 10.1 EB05 9.4 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=542 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 24,965 | 4.24.1–4.2 | signal |
| Suicidality | 15,131 | 3.03.0–3.1 | signal |
| Serious infection | 38,142 | 2.42.4–2.4 | signal |
| Interstitial lung disease | 4,348 | 2.22.1–2.3 | signal |
| Kidney injury | 20,408 | 2.22.1–2.2 | signal |
| Hyponatraemia | 3,501 | 2.12.0–2.2 | signal |
| Severe cutaneous reaction | 3,175 | 2.12.0–2.1 | raised |
| Anaemia | 12,565 | 2.02.0–2.1 | raised |
| Neutropenia / agranulocytosis | 10,247 | 2.02.0–2.0 | raised |
| Fall / fracture | 15,693 | 2.02.0–2.0 | raised |
| Gi bleeding | 7,325 | 1.91.9–2.0 | raised |
| Anaphylaxis / angioedema | 4,765 | 1.81.8–1.9 | raised |
| Thrombocytopenia | 8,293 | 1.81.8–1.8 | raised |
| Opportunistic infection | 4,755 | 1.71.6–1.7 | raised |
| Depression | 9,729 | 1.71.6–1.7 | raised |
| Arrhythmia / qt | 6,453 | 1.61.6–1.6 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 37,634 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.568 | 1.3 EB05 1.3 · IC025 +0.4 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.9 | no trial arm names this drug |
| Fatigue (tiredness) | 36,347 | 2.3 2.2–2.3ROR 2.4 · calibrated p 0.867 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.6 | no trial arm names this drug |
| Off label use (used outside approved label) | 34,857 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.949 | 1.9 EB05 1.9 · IC025 +0.9 | Reporting / coding artifact | age-adj. PRR 1.7 · serious PRR 2.3 | no trial arm names this drug |
| Nausea | 31,499 | 1.9 1.9–1.9ROR 2.0 · calibrated p 0.938 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.2 | no trial arm names this drug |
| Headache | 30,241 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.839 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 2.7 | no trial arm names this drug |
| Pain | 29,610 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.845 | 2.3 EB05 2.2 · IC025 +1.2 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 2.6 · serious PRR 2.4 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 25,002 | 1.9 1.8–1.9ROR 1.9 · calibrated p 0.898 | 1.8 EB05 1.8 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.0 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 24,055 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.998 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 2.0 | no trial arm names this drug |
| Arthralgia (joint pain) | 23,147 | 2.7 2.7–2.8ROR 2.8 · calibrated p 0.686 | 2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.4 · serious PRR 3.3 | no trial arm names this drug |
| Vomiting | 22,037 | 2.3 2.2–2.3ROR 2.3 · calibrated p 0.883 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 2.3 | no trial arm names this drug |
| Pyrexia (fever) | 20,435 | 2.9 2.9–2.9ROR 3.0 · calibrated p 0.631 | 2.8 EB05 2.7 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.5 | no trial arm names this drug |
| Rash | 18,481 | 2.1 2.0–2.1ROR 2.1 · calibrated p 0.997 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled — boxed warning exact term | age-adj. PRR 2.0 · serious PRR 2.9 | no trial arm names this drug |
| Dizziness | 18,028 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.808 | 1.7 EB05 1.7 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Asthenia (weakness) | 16,638 | 2.1 2.1–2.2ROR 2.2 · calibrated p 0.962 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.9 · serious PRR 2.0 | no trial arm names this drug |
| Toxicity to various agents | 16,635 | 5.1 5.0–5.2ROR 5.2 · calibrated p 0.210 | 4.7 EB05 4.6 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.4 · serious PRR 3.7 · 94% clinician | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Lupus vulgaris — n=792, PRR 94.1
- Rheumatic fever — n=2,807, PRR 84.8
- Deep vein thrombosis postoperative — n=1,242, PRR 81.4
- Duodenal ulcer perforation — n=4,564, PRR 77.4
- Facet joint syndrome — n=1,725, PRR 56.6
- Exposure to toxic agent — n=1,706, PRR 52.7
- Adjustment disorder with depressed mood — n=978, PRR 44.0
- Helicobacter infection — n=4,707, PRR 40.0
- Folliculitis — n=4,524, PRR 36.3
- Dislocation of vertebra — n=973, PRR 36.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Acetaminophen?
In FDA FAERS, the most frequently co-reported reaction terms for Acetaminophen are fatigue, nausea, headache, pain, diarrhoea, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Acetaminophen have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Do FAERS signals prove that Acetaminophen causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0f67c1bd-915b-4681-88dd-22f5154a80b3, effective 20240506; matched on
openfda.generic_name.exact:"ACETAMINOPHEN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 1983 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,171 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ACETAMINOPHEN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.